Justin Kim, Ph.D., of Dana-Farber Cancer Institute’s Cancer Biology Department is receiving the 2018 National Institute of Health’s New Innovator Award as part of the NIH’s Common Fund’s High-Risk, High-Reward Research Program.
The NIH Director’s New Innovator Award, established in 2007, supports unusually innovative research from early career investigators who are within 10 years of their final degree or clinical residency and have not yet received a research project grant or equivalent NIH grant. Kim is recognized among 58 other highly distinguished innovative scientists and will receive funding to further his impact on and address challenges in relation to biomedical science.
The High-Risk, High-Reward Research program is aimed at supporting compelling, high-risk research proposals that may struggle in the traditional peer review process despite their transformative potential. The program consists of four awards: The NIH Director’s Pioneer Award, New Innovator Award, Transformative Research Award and Early Independence Award.
“This program supports exceptionally innovative researchers who have the potential to transform the biomedical field,” said NIH Director Francis S. Collins, M.D., Ph.D. “I am confident this new cohort will revolutionize our approaches to biomedical research through their groundbreaking work.”
The NIH Common Fund supports a series of exceptionally high-impact, trans-NIH programs which pursue major opportunities and gaps throughout the biomedical research enterprise that are of great importance to NIH and require collaboration across the agency to succeed. Kim marks the second Dana-Farber faculty member to receive the prestigious New Innovator Award over the past 4 years.
Click here for more information on the award.